Rigel Pharmaceuticals Was Easy To Dismiss - Now It's Hard To Ignore (Rating Upgrade)

Rigel Pharmaceuticals (RIGL) is upgraded to a speculative Buy as profitability and product momentum improve. Gavreto acquisition has materially boosted revenue and is valued at ~$245M NPV, about half RIGL's market cap. Tavalisse demand surged, carving a defensible niche in ITP; Rezlidhia seeks expansion beyond AML.